Gene Therapies in Clinical Development to Treat Retinal Disorders
Molecular Diagnosis & Therapy · 2024-09 · 28 (5) · 575-591
DOI: 10.1007/s40291-024-00722-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Diagnosis & Therapy, online erschienen am 02.07.2024. Verfasst von Michelle E McClements und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Wellington Square, Oxford, OX1 2JD, UK. maclaren@ey…. Hauptthemen laut MEDLINE: Genetic Therapy, Retinal Diseases, Clinical Trials as Topic. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIHR.
Abstract (Originalsprache)
Gene therapies have emerged as promising treatments in clinical development for various retinal disorders, offering hope to patients with inherited degenerative eye conditions. Several gene therapies have already shown remarkable success in clinical trials, with significant improvements observed in visual acuity and the preservation of retinal function. A multitude of gene therapies have now been delivered safely in human clinical trials for a wide range of inherited retinal disorders but there are some gaps in the reported trial data. Some of the most exciting treatment options are not under peer review and information is only available in press release form. Whilst many trials appear to have delivered good outcomes of safety, others have failed to meet primary endpoints and therefore not proceeded to phase III. Despite this, such trials have enabled researchers to learn how best to assess and monitor patient outcomes, which will guide future trials to greater success. In this review, we consider recent and ongoing clinical trials for a variety of potential retinal gene therapy treatments and discuss the positive and negative issues related to these trials. We discuss the treatment potential following clinical trials as well as the potential risks of some treatments under investigation. As these therapies continue to advance through rigorous testing and regulatory approval processes, they hold the potential to revolutionise the landscape of retinal disorder treatments, providing renewed vision and enhancing the quality of life for countless individuals worldwide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Wellington Square, Oxford, OX1 2JD, UK. maclaren@eye.ox.ac.uk.
- Oxford University Hospital NIHR Biomedical Research Centre, Oxford, UK. maclaren@eye.ox.ac.uk.
- Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Wellington Square, Oxford, OX1 2JD, UK.
- Oxford University Hospital NIHR Biomedical Research Centre, Oxford, UK.
- Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
ORCID-Profile: Michelle E McClements
Förderung
- NIHR
Zitieren
APA
McClements, M. E., Elsayed, M. E. A. A., Major, L., de la Camara, C. M., & MacLaren, R. E. (2024). Gene Therapies in Clinical Development to Treat Retinal Disorders. Molecular Diagnosis & Therapy, 28(5), 575-591. https://doi.org/10.1007/s40291-024-00722-0
Vancouver
McClements ME, Elsayed MEAA, Major L, de la Camara CM, MacLaren RE. Gene Therapies in Clinical Development to Treat Retinal Disorders. Molecular Diagnosis & Therapy. 2024;28(5):575-591. doi:10.1007/s40291-024-00722-0
BibTeX
@article{McClements2024,
author = {McClements, Michelle E and Elsayed, Maram E A Abdalla and Major, Lauren and de la Camara, Cristina Martinez-Fernandez and MacLaren, Robert E},
title = {Gene Therapies in Clinical Development to Treat Retinal Disorders},
journal = {Molecular Diagnosis & Therapy},
year = {2024},
volume = {28},
number = {5},
pages = {575--591},
doi = {10.1007/s40291-024-00722-0}
}
EUVIMED